Welcome to LookChem.com Sign In|Join Free
  • or
Mycotoxinin I is a secondary metabolite produced by certain fungi, particularly those belonging to the Aspergillus genus. It exhibits a unique chemical structure characterized by a tricyclic core and various functional groups, which contribute to its biological activity. Mycotrienin I possesses potent antitumor properties and has been found to inhibit osteoclastic bone resorption, making it a promising candidate for pharmaceutical applications.
Source:
Mycotoxinin I is typically isolated from Streptomyces sp., a genus of Gram-positive bacteria known for producing bioactive secondary metabolites.
Production Methods:
The production of mycotrienin I involves the fermentation process using Streptomyces sp. as the host organism. The optimization of culture conditions, such as temperature, pH, and nutrient composition, is crucial for maximizing the yield of mycotrienin I.

82189-03-5

Post Buying Request

82189-03-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

82189-03-5 Usage

Uses

Used in Anticancer Applications:
Mycotoxinin I is used as an anticancer agent for its potent activity against various tumor cell lines. It modulates multiple signaling pathways involved in tumor growth and progression, making it a valuable tool in cancer therapy. Additionally, mycotrienin I has been found to significantly potentiate the action of several clinical anti-cancer agents, enhancing their efficacy and overcoming drug resistance.
Used in Bone Resorption Inhibition:
Mycotoxinin I is used as an inhibitor of osteoclastic bone resorption, a process that contributes to the development of various bone disorders, such as osteoporosis and rheumatoid arthritis. By inhibiting osteoclast activity, mycotrienin I can help maintain bone integrity and prevent the loss of bone mass.
Used in Drug Delivery Systems:
To improve the delivery, bioavailability, and therapeutic outcomes of mycotrienin I, various drug delivery systems have been developed. These systems, which may include organic and metallic nanoparticles, aim to enhance the solubility, stability, and targeted delivery of mycotrienin I, ultimately improving its efficacy in treating cancer and bone-related disorders.

Check Digit Verification of cas no

The CAS Registry Mumber 82189-03-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,2,1,8 and 9 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 82189-03:
(7*8)+(6*2)+(5*1)+(4*8)+(3*9)+(2*0)+(1*3)=135
135 % 10 = 5
So 82189-03-5 is a valid CAS Registry Number.
InChI:InChI=1/C36H48N2O8/c1-23-14-13-17-27-20-28(39)21-30(34(27)42)38-32(40)22-29(45-4)18-11-6-5-7-12-19-31(24(2)33(23)41)46-36(44)25(3)37-35(43)26-15-9-8-10-16-26/h5-7,11-12,14,18,20-21,24-26,29,31,33,41H,8-10,13,15-17,19,22H2,1-4H3,(H,37,43)(H,38,40)/b6-5+,12-7+,18-11+,23-14-/t24-,25-,29+,31+,33+/m1/s1

82189-03-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name [(4E,6R,7S,8S,10E,12E,14E,16R)-6-hydroxy-16-methoxy-5,7-dimethyl-18,22,24-trioxo-19-azabicyclo[18.3.1]tetracosa-1(23),4,10,12,14,20-hexaen-8-yl] (2R)-2-(cyclohexanecarbonylamino)propanoate

1.2 Other means of identification

Product number -
Other names ansatrienin A

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:82189-03-5 SDS

82189-03-5Upstream product

82189-03-5Relevant academic research and scientific papers

Total synthesis of (+)-mycotrienol and (+)-mycotrienin I: Application of assymetric crotylsilane bond constructions

Masse, Craig E.,Yang, Michael,Solomon, Jason,Panek, James S.

, p. 4123 - 4134 (2007/10/03)

A highly convergent asymmetric synthesis of the ansamycin antibiotics (+)-myotrienin I (1c) and (+)-mycotrienol (1d) has been achieved through the synthesis and coupling of the C9-C16 subunit 3b and the aromatic subunit 4b, respectively. This article describes the complete details of that work as it illustrates the utility of our developing chiral (E)-crotylsilane bond construction methodology in total synthesis. All four sterogenic centers were introduced using chiral allylsilane bond construction methodology. In the synthesis of subunit 3b, the C12 and C13 stereocenters were installed using an asymmetric crotylsilylation reaction to α-keto dibenzyl acetal 5. The C11 stereocenter was subsequently installed via a chelate-controlled addition of allyltrimethylsilane to establish the anti-1,3-diol system. The C14-C15 trisubstituted double bond was then installed via a reductive opening of α,β-unsaturated lactone 10b. Aromatic subunit 4b was chosen on the basis of its synthon equivalency to the amidobenzoquinone system of (+)-1c and (+)- 1d. Subunit 4b was constructed in a concise six-step sequence which corporates the C3 stereogenic center of the C1-C5 side chain. The C3 sterogenic center was established using a Weinreb amidation of aniline 18 with lactone (+)-16, whose absolute stereochemistry was derived using the crotylsilane methodology. The union of subunit 3b with aromatic subunit 4b was accomplished using a sulfone-based coupling strategy. Coupling product 21 was transformed through a sequence of steps to triene 24. Divergence from this advance intermediate allows access to both natural products. The successful completion of the synthesis included the incorporation of the (E, E, E)-triene unit with simultaneous macrocyclization through a palladium (0)- catalyzed (Stille-type) coupling macrocyclization.

(+)-Trienomycins A, B, C, and F and (+)-mycotrienins I and II: Relative and absolute stereochemistry

Smith III, Amos B.,Wood, John L.,Wong, Weichyun,Gould, Alexandra E.,Rizzo, Carmelo J.,Barbosa, Joseph,Komiyama, Kanki,Omura, Satoshi

, p. 8308 - 8315 (2007/10/03)

The complete relative and absolute stereochemistries have been elucidated for the ansamycin antibiotics (+)-trienomycins A, B, and C and their potent antifungal congeners, the (+)-mycotrienins I and II. A new species, (+)-trienomycin F, has also been isol

(+)-Mycotrienins I and II: Relative and absolute stereochemistry

Smith III,Wood,Omura

, p. 841 - 842 (2007/10/02)

The complete relative and absolute stereochemistry of the potent antifungal antibiotics (+)-mycotrienin I and (+)-mycotrienin II have been established by chemical correlation with the antitumor agent (+)-trienomycin A.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 82189-03-5